deltatrials
Terminated PHASE1 NCT00003567

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Mutant MGMT Gene Transfer Into Human Hematopoietic Progenitors to Protect Hematopoiesis During O6-Benzylguanine (BG, NSC 637037) and Carmustine Followed by Temozolomide Therapy of Advanced Solid Tumors

Sponsor: Case Comprehensive Cancer Center

Conditions Brain and Central Nervous System Tumors Lymphoma Unspecified Adult Solid Tumor, Protocol Specific
Interventions O6-benzylguanine carmustine filgrastim in vitro-treated peripheral blood stem cell transplantation sargramostim temozolomide therapeutic autologous lymphocytes
Updated 6 times since 2017 Last updated: Jun 9, 2010 Started: May 31, 1999 Primary completion: Jan 31, 2007 Completion: Feb 28, 2007

This PHASE1 trial investigates Brain and Central Nervous System Tumors and Lymphoma and is currently terminated or withdrawn. Case Comprehensive Cancer Center leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

May 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Case Comprehensive Cancer Center
  • National Cancer Institute (NCI)
Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Cleveland, United States